Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.42 +2.2%	$16.48	$9.57 ▼ $27.34	$2.22B	0.94	2.03 million shs	2.81 million shs
CNTA Centessa Pharmaceuticals	$17.02 -0.9%	$14.29	$9.60 ▼ $19.09	$2.30B	1.48	1.19 million shs	557,955 shs
IDYA IDEAYA Biosciences	$23.10 +3.1%	$22.48	$13.45 ▼ $40.74	$1.96B	0.09	1.06 million shs	849,957 shs
XNCR Xencor	$7.23 -1.2%	$8.67	$7.07 ▼ $27.24	$522.09M	0.89	608,290 shs	872,504 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.24%	+3.08%	-13.03%	+26.21%	-34.32%
CNTA Centessa Pharmaceuticals	-0.93%	+1.25%	+21.31%	+38.49%	+56.00%
IDYA IDEAYA Biosciences	+3.08%	-4.82%	+0.57%	+32.99%	-35.58%
XNCR Xencor	-1.23%	-9.40%	-22.51%	-13.21%	-53.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	4.1903 of 5 stars	4.4	2.0	3.4	2.9	1.7	0.0
CNTA Centessa Pharmaceuticals	3.0433 of 5 stars	3.5	3.0	0.0	2.1	3.3	0.6
IDYA IDEAYA Biosciences	4.181 of 5 stars	4.4	1.0	4.4	3.1	1.7	0.0
XNCR Xencor	3.4886 of 5 stars	3.4	0.0	3.9	1.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.89	Moderate Buy	$43.14	162.75% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	65.10% Upside
IDYA IDEAYA Biosciences	2.77	Moderate Buy	$48.09	108.19% Upside
XNCR Xencor	2.75	Moderate Buy	$26.43	265.54% Upside

Current Analyst Ratings Breakdown

Latest XNCR, CNTA, ARWR, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$66.00 ➝ $72.00
7/22/2025	IDYA IDEAYA Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00
7/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$57.00 ➝ $30.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	638.76	N/A	N/A	$1.54 per share	10.66
CNTA Centessa Pharmaceuticals	$6.85M	332.00	N/A	N/A	$3.05 per share	5.58
IDYA IDEAYA Biosciences	$7M	289.21	N/A	N/A	$10.95 per share	2.11
XNCR Xencor	$110.49M	4.67	N/A	N/A	$8.70 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	23.18	N/A	-47.81%	-11.95%	N/A
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	N/A
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	N/A

Latest XNCR, CNTA, ARWR, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
IDYA IDEAYA Biosciences	N/A	12.39	13.92
XNCR Xencor	N/A	5.34	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CNTA Centessa Pharmaceuticals	82.01%
IDYA IDEAYA Biosciences	98.29%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CNTA Centessa Pharmaceuticals	7.09%
IDYA IDEAYA Biosciences	2.50%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.62 million	124.15 million	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.39 million	Optionable
XNCR Xencor	280	71.32 million	67.78 million	Optionable

XNCR, CNTA, ARWR, and IDYA Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Hits New 12-Month Low Following Analyst Downgrade

4 hours ago | americanbankingnews.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8 at 11:55 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8 at 11:52 AM | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8 at 10:11 AM | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8 at 9:32 AM | finance.yahoo.com

Primecap Management Co. CA Has $103.86 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

August 8 at 5:39 AM | marketbeat.com

XTX Topco Ltd Acquires 35,627 Shares of Xencor, Inc. (NASDAQ:XNCR)

August 7 at 3:38 AM | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

August 6 at 6:36 PM | zacks.com

Xencor (XNCR) to Release Earnings on Monday

August 3, 2025 | americanbankingnews.com

Short Interest in Xencor, Inc. (NASDAQ:XNCR) Rises By 127,291.3%

August 3, 2025 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Short Interest Update

August 2, 2025 | marketbeat.com

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

July 31, 2025 | finance.yahoo.com

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $28.00

July 31, 2025 | americanbankingnews.com

Xencor (XNCR) Projected to Post Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $528,000 in Xencor, Inc. (NASDAQ:XNCR)

July 28, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Brokerages

July 28, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR, CNTA, ARWR, and IDYA Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.42 +0.36 (+2.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$16.41 -0.01 (-0.06%)

As of 08/8/2025 07:27 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$17.02 -0.16 (-0.93%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$17.00 -0.02 (-0.09%)

As of 08/8/2025 05:57 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

IDEAYA Biosciences NASDAQ:IDYA

$23.10 +0.69 (+3.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$23.09 -0.01 (-0.04%)

As of 08/8/2025 05:30 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Xencor NASDAQ:XNCR

$7.23 -0.09 (-1.23%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.24 +0.00 (+0.07%)

As of 08/8/2025 06:23 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time